Potential and emerging therapeutics for HHT
Authors:
- 6 December 2024
- journal article
- case report
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2024 (1) , 724-727
Abstract
A 64-year-old woman with hereditary hemorrhagic telangiectasia (HHT) characterized by a pathological variant in ACVRL1 presents to the clinic for follow-up. Manifestations of HHT include frequent epistaxis and gastrointestinal bleeding, leading to iron-deficiency anemia. Bevacizumab is initiated, with resolution of the anemia. While maintained on a regimen of bevacizumab every 6 weeks, she continues to report frequent epistaxis and has ongoing iron-deficiency requiring periodic iron infusions. She also finds the bevacizumab infusions inconvenient. She is interested in discussing other options for managing her disease.Keywords
This publication has 32 references indexed in Scilit:
- A Case of High-Output Heart FailureChest, 2022
- Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasiaAngiogenesis, 2021
- SMAD4 mutation and the combined juvenile polyposis and hereditary hemorrhage telangiectasia syndrome: a single center experienceInternational Journal of Colorectal Disease, 2020
- Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasiaAngiogenesis, 2018
- Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia–Related Epistaxis and Gastrointestinal BleedingMayo Clinic Proceedings, 2018
- Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 studyThe Lancet Haematology, 2015
- Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatmentAngiogenesis, 2013
- BMP9 Mutations Cause a Vascular-Anomaly Syndrome with Phenotypic Overlap with Hereditary Hemorrhagic TelangiectasiaThe American Journal of Human Genetics, 2013
- Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac OutputJAMA, 2012
- Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasiaLiver Transplantation, 2008